{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:18:10Z","timestamp":1761506290825,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.cllc.2022.07.001","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T02:41:13Z","timestamp":1658371273000},"page":"578-584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7080-4835","authenticated-orcid":false,"given":"Fatemeh","family":"Ardeshir-Larijani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra K.","family":"Althouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ticiana","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence Eric","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taher Abu","family":"Hejleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malini","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan D.","family":"Gentzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam Ryan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasser H","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2022.07.001_bib0001","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013Carboplatin Alone or with Bevacizumab for Non\u2013Small-Cell Lung Cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.001_bib0002","doi-asserted-by":"crossref","first-page":"14698","DOI":"10.1038\/srep14698","article-title":"Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis","volume":"5","author":"Li","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2022.07.001_bib0003","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.semcancer.2017.12.002","article-title":"Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics","volume":"52","author":"Hegde","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.cllc.2022.07.001_bib0004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/PPO.0000000000000327","article-title":"Combinations of bevacizumab with cancer immunotherapy","volume":"24","author":"Chen","year":"2018","journal-title":"The Cancer Journal"},{"key":"10.1016\/j.cllc.2022.07.001_bib0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2022.07.001_bib0006","doi-asserted-by":"crossref","first-page":"ix186","DOI":"10.1093\/annonc\/mdz446.002","article-title":"LBA3 - IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo)\u00a0+\u00a0bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"30","author":"Cheng","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.07.001_bib0007","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.07.001_bib0008","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Non-squamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.001_bib0009","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3816\/CLC.2009.n.035","volume":"10","author":"Patel","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2022.07.001_bib0010","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.07.001_bib0011","doi-asserted-by":"crossref","first-page":"539.e537","DOI":"10.1016\/j.amjmed.2014.11.025","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs","volume":"128","author":"Kim","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.cllc.2022.07.001_bib0012","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1535-7163.MCT-06-0343","article-title":"Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications","volume":"6","author":"Chattopadhyay","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cllc.2022.07.001_bib0013","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/sj.bjc.6603995","article-title":"Pemetrexed pharmacokinetics and pharmacodynamics in a phase I\/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules","volume":"97","author":"Li","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2022.07.001_bib0014","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.001_bib0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jtho.2020.09.015","article-title":"Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC","volume":"16","author":"Awad","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.07.001_bib0016","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/annonc\/mdp533","article-title":"Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review","volume":"21","author":"Welch","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.07.001_bib0017","doi-asserted-by":"crossref","first-page":"10703","DOI":"10.18632\/oncotarget.12926","article-title":"Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2022.07.001_bib0018","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/JTO.0000000000000366","volume":"10","author":"Zinner","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2022.07.001_bib0019","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin\u2013gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.07.001_bib0020","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1200\/JCO.2012.47.9626","volume":"31","author":"Patel","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.07.001_bib0021","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14740338.2020.1767584","article-title":"The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer","volume":"19","author":"Manzo","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cllc.2022.07.001_bib0022","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/PPO.0000000000000327","article-title":"Combinations of Bevacizumab With Cancer Immunotherapy","volume":"24","author":"Chen","year":"2018","journal-title":"Cancer J"},{"key":"10.1016\/j.cllc.2022.07.001_bib0023","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2022.07.001_bib0024","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41467-019-11584-0","article-title":"Mild replication stress causes chromosome mis-segregation via premature centriole disengagement","volume":"10","author":"Wilhelm","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.cllc.2022.07.001_bib0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s11658-019-0164-y","article-title":"Progress in research on paclitaxel and tumor immunotherapy","volume":"24","author":"Zhu","year":"2019","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.cllc.2022.07.001_bib0026","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2022.07.001_bib0027","doi-asserted-by":"crossref","first-page":"viii743","DOI":"10.1093\/annonc\/mdy424.066","article-title":"IMpower132: Efficacy of atezolizumab (atezo)+ carboplatin (carbo)\/cisplatin (cis)+ pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC)","volume":"29","author":"Barlesi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2022.07.001_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cllc.2022.07.001_bib0029","doi-asserted-by":"crossref","first-page":"e65757","DOI":"10.1371\/journal.pone.0065757","article-title":"Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models","volume":"8","author":"Shi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2022.07.001_bib0030","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s12032-013-0777-3","article-title":"Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models","volume":"31","author":"Tao","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.cllc.2022.07.001_bib0031","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422001577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730422001577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:02Z","timestamp":1761506042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730422001577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1525730422001577"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.07.001","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}